Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin and pioglitazone in type 2 diabetes with inadequate control on diet and exercise
2007-001771-11Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of sitagliptin and pioglitazone in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Merck & Co. Primary endpoints: Total glucose AUC during meal tolerance test and Post-prandial glucagon AUC during meal tolerance test. Started Jul 2007; status: completed.
02
Drugs
sitagliptinpioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2007-001771-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001771-11.